U.S. Topical Pain Relief Market by Therapeutic Class (Non-Opioids and Opioids), Formulation (Cream, Gel, Spray, Patch, and Others), Type (Prescription Pain Relief and Over-the-Counter Pain Relief), and Distribution Channel (Pharmacies & Drug Stores, E-Commerce, and Retail & Grocery Stores)- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The U.S. Topical Pain Relief market size was exhibited at USD 3.24 billion in 2022 and is projected to hit around USD 4.71 billion by 2032, growing at a CAGR of 4.15% during the forecast period 2023 to 2032.

Key Pointers:

• The study provides an in-depth analysis of the U.S. topical pain relief market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers U.S. topical pain relief market analysis from 2023 to 2032, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
• A comprehensive analysis of factors that drive and restrain the growth of the U.S. topical pain relief market is provided. 
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and U.S. Topical pain relief Market growth.

U.S. Topical Pain Relief Market Report Scope

Topical pain relief medications are applied directly to the epidermal layer of the skin at the area of inflammation or pain. Topical pain relief products are designed to relieve pain and utilize skin as the vehicle for drug administration and exert major action at the targeted site & in the central nervous system. These formulations are analgesic or anesthetic agents which are applied on or around the painful site. The aim is to offer a slow and gradual release of pain relief medication into the bloodstream by keeping the blood levels relatively constant for a certain period of time. These medications offer lesser side effects as compared to oral medications. Topical pain relievers include the administration of non-opioids and opioids drugs. Non-opioids drugs include nonsteroidal anti-inflammatory drugs (NSAIDS), methyl salicylates, capsaicin, lidocaine, and other non-opioids. Opioids drugs include buprenorphine and fentanyl.

The growth of the U.S. topical pain relief market is majorly driven by increase in prevalence of arthritis and other bone-related conditions, diabetic neuropathy, leading to pain. Other factors that boost the U.S. topical pain relief market growth include rise in adoption of topical pain relief products as they cause lesser side effects as compared to oral pain relief, upsurge in geriatric population across the U.S., and increase in demand for topical pain relief by sports players. However, factors such as topical pain relief medications can cause irritated skin and they have a strong odor or unpleasant smell that hamper the market growth. Conversely, the development of online platform for the topical therapeutics is expected to provide lucrative growth opportunities for the market.

The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. Nationwide lockdown, government regulations, and continuous increase in infection rate across the country created a widespread financial impact on clinics and pain services. Large number of clinics and pain services has witnessed a drop in number of patient visits amid COVID-19 ultimately reducing client contact. Moreover, most chronic pain facilities were deemed non-urgent, both outpatient and elective interventional procedures were limited or stopped during the COVID-19 pandemic to minimize risk of the viral spread. Thus, a negative impact of COVID-19 on opioids topical pain relief market is observed.

U.s. Topical Pain Relief Market Segmentation  

The U.S. topical pain relief market is segmented into therapeutic class, type, formulation, and distribution channel. On the basis of therapeutic class, the market is bifurcated into non-opioids and opioids. The non-opioids segment is further divided into nonsteroidal anti-inflammatory drugs (NSAIDS), methyl salicylate, capsaicin, lidocaine, and other non-opioids. The opioids segment is further bifurcated into buprenorphine and fentanyl. On the basis of type, the market is segmented into prescription pain relief and over-the-counter (OTC) relief. On the basis of formulation, the market is classified into cream, gel, spray, patch, and others. The distribution channels covered in the study include pharmacies & drug stores, e-commerce, and retail & grocery stores.

Segment review 

Presently, on the basis of therapeutic class, non-opioids segment is the major revenue contributor, and is projected to grow significantly during the forecast period due to its preferable use over the opioid drugs for treatment of mild to moderate pain. Due to less side effects as compared to opioids and no substance abuse, non-opioids are the preferred choice for the treatment of pain. However, due to restricted analgesic effects of the non-opioid drugs, their use is limited for the treatment of severe pain. 

Increase in awareness regarding adverse effects of non-opioids, surge in number of geriatric population, growth in number of patients with chronic pain, rise in prevalence of arthritis and other joint problems, majorly drive the growth of this segment. Arthritis is one of the most common and widely spread disorder that affects millions of people in the U.S. According to Centers for Disease Control and Prevention data, approximately 23.8% of total adult population was affected by arthritis in 2017.

According to distribution channel, the market is classified into pharmacies & drug stores, e-commerce, and retail & grocery stores. The e-commerce segment is anticipated to depict significant growth during the forecast period due to rise in preference for online purchase of drugs over the traditional methods, increase in awareness of online pharmacy, and rise in number of internet users. 

Some of the prominent players in the U.S. Topical Pain Relief Market include:

• ADVACARE PHARMA
• GLAXOSMITHKLINE PLC (GSK)
• JOHNSON & JOHNSON
• NESTLÉ S.A.
• NOVARTIS AG
• PFIZER INC.
• RECKITT BENCKISER GROUP PLC
• SANOFI
• SUN PHARMACEUTICAL INDUSTRIES LTD.
• TOPICAL BIOMEDICS, INC.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global U.S. Topical Pain Relief market.

By Therapeutic Class

• Non-opioids
  • Nonsteroidal anti-inflammatory drug (NSAIDS)
  • Methyl Salicylate
  • Capsaicin
  • Lidocaine
  • Other Non-opioids
• Opioids
  • Buprenorphine
  • Fentanyl

By Formulation

• Cream
• Gel
• Spray
• Patch
• Others

By Type

• Prescription Pain Relief
• Over-the-counter (OTC) Pain Relief

By Distribution Channel

• Pharmacy & Drug Store
• E-Commerce
• Retail & Grocery Store